AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26335066 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior deformation of the peripapillary RPE/basement membrane layer
Number of subjects: 165
Study 26335066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision loss
Number of subjects: 165
Study 26335608 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI+bevacizumab (BEV)
Number of subjects: 90
Study 26335907 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal treatment (RCT)
Number of subjects: 708
Study 26335961 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative integrated cycler PCR (qicPCR)
Number of subjects: 53
Study 26335961 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV entry inhibitor GS-5806
Number of subjects: 53
Study 26336199 — intervention group
Group type: EXPERIMENTAL
Intervention: Wei-Lachin multivariate one-directional test
Number of subjects: 0
Study 26336199 — intervention group
Group type: COMPARATOR
Intervention: Traditional composite outcome analysis
Number of subjects: 0
Study 26336372 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions (counseling, medications, and follow-up calls)
Number of subjects: 9500
Study 26336372 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated systems (interactive voice response and website) for treatment delivery
Number of subjects: 9500
Study 26336372 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor or automated system report versus patient report for treatment enactment
Number of subjects: 9500
Study 26336372 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9500
Study 26336510 — intervention group
Group type: EXPERIMENTAL
Intervention: A-Part Gel(®) as an anti-adhesive barrier
Number of subjects: 62
Study 26336510 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 62
Study 26336510 — intervention group
Group type: EXPERIMENTAL
Intervention: A-Part Gel(®)
Number of subjects: 62
Study 26336608 — intervention group
Group type: EXPERIMENTAL
Intervention: CT carriers (polymorphism carriers)
Number of subjects: 40
Study 26336609 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin (glargine, starting dose 0.1 U/kg/day)
Number of subjects: 150
Study 26336609 — intervention group
Group type: COMPARATOR
Intervention: Oral antidiabetic drug (OAD) therapy
Number of subjects: 150
Study 26336609 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin
Number of subjects: 150
Study 26336609 — intervention group
Group type: COMPARATOR
Intervention: OAD
Number of subjects: 150
Study 26336930 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab treatment
Number of subjects: 15
Study 26336946 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP indication
Number of subjects: 180
Study 26336946 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP interest
Number of subjects: 180
Study 26336946 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of recent anal sex partners
Number of subjects: 180
Study 26336946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower collective self-esteem scores
Number of subjects: 180
Study 26336946 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP uptake
Number of subjects: 180
Study 26337035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular occlusion test (VOT) performed three times per patient: prior to induction of anesthesia, at the end of surgery, and on postoperative day 1.
Number of subjects: 254
Study 26337035 — intervention group
Group type: EXPERIMENTAL
Intervention: Low VOT recovery slope on postoperative day 1.
Number of subjects: 254
Study 26337145 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg subcutaneous injections at 4-week intervals
Number of subjects: 9
Study 26337346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) from patients with CRS
Number of subjects: 37
Study 26337354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 0
Study 26337493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (single-agent treatment)
Number of subjects: 0
Study 26337664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant)
Number of subjects: 39
Study 26337806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (4.0 mg) plus lenalidomide (25 mg) and dexamethasone (40 mg)
Number of subjects: 43
Study 26338094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg every 3 weeks (Q3W)
Number of subjects: 29
Study 26338094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg every 4 weeks (Q4W)
Number of subjects: 29
Study 26338094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg Q3W
Number of subjects: 29
Study 26338094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg Q4W
Number of subjects: 29
Study 26338094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran (all doses)
Number of subjects: 29
Study 26338109 — intervention group
Group type: EXPERIMENTAL
Intervention: Major complications
Number of subjects: 47
Study 26338109 — intervention group
Group type: COMPARATOR
Intervention: Minor or no complications
Number of subjects: 47
Study 26338178 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 14
Study 26338178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour subvolume analysis
Number of subjects: 14
Study 26338178 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial mismatch analysis
Number of subjects: 14
Study 26338886 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) assessment of energy intake (EI)
Number of subjects: 253
Study 26338888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage (SSB) intake >0 but <2 servings/week
Number of subjects: 613
Study 26338888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage (SSB) intake ≥2 but <7 servings/week
Number of subjects: 613
Study 26338888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage (SSB) intake ≥7 servings/week
Number of subjects: 613
Study 26338888 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in SSB intake by ≥1 serving/week
Number of subjects: 613
Study 26338888 — intervention group
Group type: COMPARATOR
Intervention: Stable SSB intake
Number of subjects: 613
Study 26338888 — intervention group
Group type: COMPARATOR
Intervention: Increase in SSB intake
Number of subjects: 613
Study 26339493 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQoL (self-rated health grade)
Number of subjects: 1421
Study 26339493 — intervention group
Group type: COMPARATOR
Intervention: RAND-36 HRQOL measures
Number of subjects: 1421
Study 26339493 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis of HRQOL determinants (EuroQoL)
Number of subjects: 1421
Study 26339493 — intervention group
Group type: COMPARATOR
Intervention: General population comparison
Number of subjects: 1421
Study 26339729 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 repetition maximum-loaded knee extensions until contraction failure
Number of subjects: 24
Study 26340968 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (r-hGH)
Number of subjects: 94
Study 26341049 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol overuse (3 or more canisters per year)
Number of subjects: 416
Study 26341049 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol use on symptom days (80% or more)
Number of subjects: 416
Study 26341049 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol use on symptom-free days (less than 20%)
Number of subjects: 416
Study 26341049 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller medication adherence (80% or more of prescribed doses)
Number of subjects: 416
Study 26341049 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms
Number of subjects: 416
Study 26341131 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously administered glucagon at a dose of 2 µg/kg (total mean dose of 1,126 µg over 16 h)
Number of subjects: 11
Study 26341131 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin action model
Number of subjects: 11
Study 26341256 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Vienna Prediction Model (low risk classification)
Number of subjects: 156
Study 26341256 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Vienna Prediction Model (higher risk classification)
Number of subjects: 156
Study 26341256 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve
Number of subjects: 156
Study 26341632 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosine (early glycation)
Number of subjects: 187
Study 26341632 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosepane and pentosidine crosslinks, methylglyoxal hydroimidazolones (MG-H1), pepsin solubility
Number of subjects: 187
Study 26341632 — intervention group
Group type: EXPERIMENTAL
Intervention: MG-H1
Number of subjects: 187
Study 26341632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsin solubility
Number of subjects: 187
Study 26341632 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosine and MG-H1
Number of subjects: 187
Study 26341632 — intervention group
Group type: EXPERIMENTAL
Intervention: CML
Number of subjects: 187
Study 26341632 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosine
Number of subjects: 187
Study 26341632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower collagen pepsin solubility
Number of subjects: 187
Study 26341632 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosepane
Number of subjects: 187
Study 26341710 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade endometrioid cases
Number of subjects: 4609
Study 26341710 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade endometrioid cases
Number of subjects: 4609
Study 26341710 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-endometrioid cases (serous)
Number of subjects: 4609
Study 26341710 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-endometrioid cases (carcinosarcoma)
Number of subjects: 4609
Study 26341991 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism spectrum disorder
Number of subjects: 102
Study 26341991 — intervention group
Group type: COMPARATOR
Intervention: Matched classmates without autism spectrum disorder
Number of subjects: 102
Study 26342484 — intervention group
Group type: EXPERIMENTAL
Intervention: Port catheters (PC)
Number of subjects: 448
Study 26342484 — intervention group
Group type: COMPARATOR
Intervention: Peripherally inserted central catheters (PICC)
Number of subjects: 448
Study 26343039 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with AIT
Number of subjects: 32
Study 26343039 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study 26343101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal magnesium chloride solution (4 sprays per limb twice daily for 4 weeks)
Number of subjects: 40
Study 26343110 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone
Number of subjects: 0
Study 26343110 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 26343110 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel survival-prolonging therapeutics
Number of subjects: 0
Study 26343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy for Arabic children with pain score 7 to 10 (99.05%)
Number of subjects: 3782
Study 26343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy for Jewish children with pain score 7 to 10 (99.08%)
Number of subjects: 3782
Study 26343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy for Arabic children approached by Arabic nurses (98.9%)
Number of subjects: 3782
Study 26343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy for Arabic children approached by Jewish nurses (99%)
Number of subjects: 3782
Study 26343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy for Jewish children approached by Jewish nurses (98.9%)
Number of subjects: 3782
Study 26343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy for Jewish children approached by Arab nurses (98.9%)
Number of subjects: 3782
Study 26343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy for Arabic children during conflict (100%)
Number of subjects: 3782
Study 26343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy for Jewish children during conflict (96%)
Number of subjects: 3782
Study 26343948 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT Roadmap (health IT tool)
Number of subjects: 0
Study 26343948 — intervention group
Group type: EXPERIMENTAL
Intervention: User-centered Design Groups
Number of subjects: 0
Study 26343949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tevagrastim (biosimilar filgrastim, XMO2)
Number of subjects: 24
Study 26343949 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 24
Study 26343949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tevagrastim
Number of subjects: 24
Study 26344676 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 58
Study 26344676 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 58
Study 26345182 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed strategy (PD)
Number of subjects: 500
Study 26345182 — intervention group
Group type: COMPARATOR
Intervention: Multi-faceted strategy (MF)
Number of subjects: 500
Study 26346055 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite infection
Number of subjects: 2579
Study 26346055 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlikely infection
Number of subjects: 2579
Study 26346055 — intervention group
Group type: COMPARATOR
Intervention: None or possible infection
Number of subjects: 2579
Study 26346136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular methotrexate (MTX)
Number of subjects: 240
Study 26346468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 157
Study 26346468 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 157
Study 26346877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopic surgery
Number of subjects: 60
Study 26346877 — intervention group
Group type: COMPARATOR
Intervention: Age-matched and gender-matched reference group
Number of subjects: 60
Study 26347018 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation and Guided Imagery (PMR and GI)
Number of subjects: 236
Study 26347018 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study 26347355 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight obese (NWO) women
Number of subjects: 79
Study 26347355 — intervention group
Group type: COMPARATOR
Intervention: Normal weight lean (NWL) women
Number of subjects: 79
Study 26347355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-obese-obese (PreOB/OB) women
Number of subjects: 79
Study 26348120 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 3777
Study 26348120 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no patient navigation)
Number of subjects: 3777
Study 26348350 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary aldosterone (UAldo) measured at day 0, day 3, month 1, and month 3 postnatal in Group 1 (<33 GW)
Number of subjects: 155
Study 26348350 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma aldosterone measured in umbilical cord blood
Number of subjects: 155
Study 26348350 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone/renin ratio
Number of subjects: 155
Study 26348350 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between UAldo and urinary Na/K ratio
Number of subjects: 155
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 34636
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 34636
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery room intubation
Number of subjects: 34636
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal steroid use
Number of subjects: 34636
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure without ventilation
Number of subjects: 34636
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset sepsis
Number of subjects: 34636
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia
Number of subjects: 34636
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival at 23 weeks' gestation
Number of subjects: 34636
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival at 24 weeks' gestation
Number of subjects: 34636
Study 26348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival without major morbidity for infants at 25 to 28 weeks' gestation
Number of subjects: 34636
Study 26348869 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched sibling donor marrow transplantation following reduced intensity conditioning (RIC) with alemtuzumab, fludarabine, and melphalan
Number of subjects: 52
Study 26349473 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib 300 mg plus afatinib 30 mg (Schedule A)
Number of subjects: 57
Study 26349473 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib 300 mg plus afatinib 70 mg (Schedule B)
Number of subjects: 57
Study 26349473 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib 150-300 mg (Schedule A)
Number of subjects: 57
Study 26349473 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib 150-300 mg (Schedule B)
Number of subjects: 57
Study 26349786 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography for left ventricular ejection fraction (LVEF), wall motion score index (WMSI), and strain parameters; coronary angiography (CA) within 2 ± 1 days after admission.
Number of subjects: 268
Study 26349821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amoxicillin-clavulanic acid (25 to 35 mg/kg of body weight every 6 h)
Number of subjects: 50
Study 26349821 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations for dosing
Number of subjects: 50
Study 26349821 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h infusion for patients with augmented renal function
Number of subjects: 50
Study 26349821 — intervention group
Group type: EXPERIMENTAL
Intervention: Current dosing regimens
Number of subjects: 50
Study 26349823 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g every 8 h
Number of subjects: 15
Study 26349823 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent intermittent bolus dosing, extended and continuous infusion
Number of subjects: 15
Study 26349823 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of piperacillin
Number of subjects: 15
Study 26351026 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 44
Study 26351026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise training)
Number of subjects: 44
Study 26351289 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with myocardial infarction (MI)
Number of subjects: 480
Study 26351289 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with multivessel disease
Number of subjects: 480
Study 26351289 — intervention group
Group type: COMPARATOR
Intervention: Women with MI
Number of subjects: 480
Study 26351289 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with MI
Number of subjects: 480
Study 26351323 — intervention group
Group type: EXPERIMENTAL
Intervention: AKT inhibitor AZD5363
Number of subjects: 0
Study 26351323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AZD5363 and FGFR inhibitor AZD4547
Number of subjects: 0
Study 26351323 — intervention group
Group type: EXPERIMENTAL
Intervention: Allosteric AKT inhibitor MK-2206 and catalytic AKT inhibitor AZD5363
Number of subjects: 0
Study 26351323 — intervention group
Group type: COMPARATOR
Intervention: AZD5363 monotherapy
Number of subjects: 0
Study 26351392 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine, administered in the years 2009-2010 and 2010-2011.
Number of subjects: 255
Study 26352686 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (960 mg twice daily)
Number of subjects: 28
Study 26352814 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 75
Study 26352814 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 75
Study 26352815 — intervention group
Group type: EXPERIMENTAL
Intervention: CTL019 cells infusion after myeloablative chemotherapy (melphalan, 140 mg/m²) and autologous stem-cell transplantation
Number of subjects: 1
Study 26352815 — intervention group
Group type: COMPARATOR
Intervention: Higher dose melphalan (200 mg/m²) followed by autologous transplantation
Number of subjects: 1
Study 26354094 — intervention group
Group type: EXPERIMENTAL
Intervention: Any or combination of metformin, clomiphene citrate (CC), letrozole, and gonadotropins
Number of subjects: 0
Study 26354094 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26354529 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum folate >26.3 ng/mL
Number of subjects: 100
Study 26354529 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin B-12 >701 pg/mL
Number of subjects: 100
Study 26354529 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum folate and vitamin B-12 concentrations greater than the median
Number of subjects: 100
Study 26354529 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum concentrations of folate and vitamin B-12 before ART treatment
Number of subjects: 100
Study 26354543 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat intake
Number of subjects: 50345
Study 26354543 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprocessed red meat intake
Number of subjects: 50345
Study 26354543 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat intake after adjustment for BMI
Number of subjects: 50345
Study 26354543 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprocessed red meat intake after adjustment for BMI
Number of subjects: 50345